Study #2022-0451
A phase II study evaluating the effect of GEN-1 (IL-12 Plasmid Formulated with PEG-PEI-Cholesterol Lipopolymer) on second look laparoscopy (SLL) when administered in combination with Bevacizumab (BEV) and Neoadjuvant Chemotherapy (NACT) in subjects newly diagnosed with advanced ovarian, fallopian tube or primary peritoneal cancer
MD Anderson Study Status
Enrolling
Treatment Agent
Paclitaxel, Carboplatin, Bevacizumab, IMNN-001
Description
This is a 1:1 randomized, open label, multi-center phase I/II trial to evaluate the safety, dosing, efficacy, and biological activity of adding IMNN-001 to chemotherapy + BEV compared to chemotherapy + BEV alone.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
Study phase:
Physician name:
Amir Jazaeri
Department:
Gynecologic Oncology & Reproductive Medicine
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.